{'fraction_non_alphanumeric': 0.022704837117472853, 'fraction_numerical': 0.006910167818361303, 'mean_word_length': 5.627450980392157, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Antibiotic Elution from Hydroxyapatite Cement Cranioplasty Materials

Hydroxyapatite cements (HAC) are a contemporary material used for multiple cranioplasty applications. In an effort to decrease the risk of postoperative infection, mixing antibiotics into the material during intraoperative application is frequently done. It has been assumed, but never substantiated, that significant antibiotic release from the material occurs after implantation. Using standardized morphologies, a mixture of a specific HAC (Mimix bone void filler) and tobramycin antibiotic was prepared, hydrated in phosphate-buffered saline, and tested in vitro for as long as 22 days after preparation. The results show that the majority of the antibiotic (91%) was released within the first 24 hours, with the balance being eluted during the next 8 days. Overall, the release of tobramycin from Mimix bone void filler appears to fit the pattern of antibiotic release demonstrated to occur from other bioabsorbable ceramic-type carriers.